Creative Touch Permanent Makeup and Aesthetics

Acetyl-CoA is the two-carbon metabolic currency at the convergence of virtually every major fuel pathway. Glucose, fatty acids, and certain amino acids all ultimately produce it; from this single molecular hub, the cell decides whether to generate ATP via the TCA cycle, synthesise new lipids and sterols, or regulate gene expression through histone acetylation. The acetyl-CoA/ CoA ratio is one of the primary signals driving the Randle Cycle – rising fatty acid oxidation elevates this ratio and chemically suppresses glucose utilisation at multiple points in the glycolytic pathway. In the skin specifically, cytosolic acetyl-CoA is the obligate raw material for the fatty acid elongation that produces the very long-chain ceramides most critical to barrier integrity. A 2025 mouse study (Nguyen et al., Cell Reports) demonstrated that disrupted skin acetyl-CoA synthesis depletes these barrier ceramides even when exogenous fatty acids are plentiful – pointing to a metabolic upstream component in barrier lipid quality that topical products alone cannot address. ^[3]

Acetyl-CoA (acetyl coenzyme A) is a two-carbon thioester molecule – an acetyl group (CH₃CO–) attached to coenzyme A via a high-energy sulphur bond – that functions as the central metabolic currency connecting virtually every fuel pathway in the cell. Derived from the catabolism of glucose, fatty acids, and certain amino acids, it is the convergence point where all three macronutrient breakdown routes meet before entering the tricarboxylic acid (TCA) cycle for energy production. Its functions extend well beyond energy: acetyl-CoA is simultaneously the building block for all de novo fatty acid and sterol synthesis and the acetyl donor for histone acetyltransferases, directly linking the cell’s nutritional state to its gene expression programme. Research from Shi and Tu (2015) established it as a “sentinel metabolite” – one that cells actively monitor as a continuous gauge of metabolic state. ^[5]

Three Fuels, One Molecule

The three major fuel inputs each produce acetyl-CoA through distinct enzymatic pathways.

From glucose: glycolysis converts glucose to pyruvate, which the pyruvate dehydrogenase complex (PDH) then catalyses to acetyl-CoA inside the mitochondrial matrix. This is a committed, irreversible step: once pyruvate becomes acetyl-CoA, those carbon atoms cannot return to gluconeogenesis. PDH regulation is covered in its own entity; what matters here is that its inhibition by rising acetyl-CoA and NADH is the primary molecular mechanism by which fatty acid oxidation suppresses glucose utilisation in the Randle Cycle. ^[2]

From fatty acids: long-chain fatty acids enter the mitochondria via the carnitine shuttle – gated by carnitine palmitoyltransferase-1 (CPT-1) – and undergo β-oxidation, a stepwise removal of two-carbon units that yields one acetyl-CoA molecule per cycle alongside NADH and FADH₂. A 16-carbon palmitic acid yields eight acetyl-CoA molecules. This route generates acetyl-CoA rapidly and at high volume when fat is the dominant fuel, as during fasting or sustained aerobic exercise.

From amino acids: leucine, lysine, isoleucine, tryptophan, and threonine are ketogenic, meaning their catabolism produces acetyl-CoA directly; others enter via acetoacetate or acetyl-CoA synthetase routes. This is a minor fuel source under normal nutritional conditions but becomes relevant during prolonged fasting or states where muscle protein is being mobilised.

Two Compartments, Two Agendas

Acetyl-CoA cannot cross the inner mitochondrial membrane directly. This impermeability creates a functionally significant compartmental distinction: mitochondrial acetyl-CoA and cytosolic/nuclear acetyl-CoA serve different purposes and are connected only indirectly through the citrate shuttle. ^[5]

Mitochondrial acetyl-CoA is directed primarily toward energy generation. Citrate synthase condenses it with oxaloacetate to form citrate, entering the TCA cycle to generate NADH and FADH₂ for oxidative phosphorylation. When energy demand is met and oxaloacetate is drawn away for gluconeogenesis – as occurs in the liver during fasting – excess mitochondrial acetyl-CoA is packaged into ketone bodies (acetoacetate and beta-hydroxybutyrate) for export to the brain and cardiac muscle.

Cytosolic/nuclear acetyl-CoA serves biosynthesis and epigenetic regulation. Under nutrient-replete conditions, mitochondria generate citrate in excess of TCA cycle demand; that citrate is exported to the cytosol, where ATP citrate lyase (ACLY) cleaves it back to acetyl-CoA and oxaloacetate. This cytosolic pool then serves three parallel functions: de novo fatty acid synthesis (via ACC → malonyl-CoA → fatty acid synthase), cholesterol synthesis (via the HMG-CoA reductase pathway), and histone acetylation as the acetyl donor for histone acetyltransferase enzymes. All three processes share a single upstream chokepoint: ACLY activity and the abundance of mitochondrially derived citrate. ^[3]

The direction of citrate traffic – whether it is oxidised in the TCA cycle or exported for cytosolic synthesis – is a metabolic state decision, not a downstream consequence of it. In the fed state, citrate export predominates and cytosolic acetyl-CoA is high; in the fasted state, mitochondrial oxidation predominates and cytosolic acetyl-CoA falls. This is the mechanism by which nutritional state writes itself into gene expression and lipid biosynthesis.

Acetyl-CoA as a Metabolic Sensor

Cells do not merely use acetyl-CoA as a substrate; they monitor its abundance as a continuous readout of their nutritional state. The mechanism runs through histone acetylation: acetyl-CoA is the obligate acetyl donor for histone acetyltransferases (HATs), which attach acetyl groups to lysine residues on histone tails. Histone acetylation relaxes chromatin and promotes transcription of the associated genes. When cytosolic and nuclear acetyl-CoA is elevated – characteristic of carbohydrate-replete or energy-surplus states – growth genes, lipid synthesis genes, and cell cycle genes are transcriptionally upregulated. When it falls – in fasting, caloric deficit, or sustained exercise – these growth programmes are suppressed and autophagy genes are de-repressed. ^[5]

The counterpart to this system is the sirtuin family of NAD⁺-dependent deacetylases, which remove acetyl groups from histones and from hundreds of other proteins including metabolic enzymes. Sirtuin activity depends on NAD⁺ availability; in fasted or exercised states, rising NAD⁺ alongside falling acetyl-CoA increases sirtuin activity, collectively shifting gene expression toward stress resistance, cellular repair, and fat utilisation. The coupling of acetyl-CoA abundance with NAD⁺/NADH status means both halves of the system – writing acetylation marks and removing them – are responsive to the same metabolic context. ^[5]

An additional layer: high mitochondrial acetyl-CoA concentrations, produced during intensive fat oxidation, can drive spontaneous non-enzymatic acetylation of mitochondrial proteins. SIRT3, a mitochondrial deacylase, removes these unintended modifications; its expression increases specifically under fasting, high-fat feeding, and exercise – precisely the states in which mitochondrial acetyl-CoA accumulation is highest. This “protein quality control” function of sirtuins in the mitochondria is now understood as a structural requirement of metabolic states in which fat oxidation is high. ^[5]

Clinical Pearl Intermittent fasting, carbohydrate restriction, and sustained aerobic exercise all lower cytosolic acetyl-CoA whilst simultaneously raising NAD⁺. This engages sirtuin activity and shifts gene expression toward cellular maintenance and fat utilisation. The metabolic benefit of these interventions is not purely caloric; it reflects a genuine epigenetic signal that the cell monitors through acetyl-CoA abundance. The acetyl-CoA/NAD⁺ axis is the molecular mechanism underlying the observation that whole-food dietary patterns and regular movement influence cellular ageing processes at the chromatin level.

The Randle Cycle: Acetyl-CoA as the Signal

The Randle Cycle – the reciprocal competition between glucose and fatty acids for cellular oxidation – operates through acetyl-CoA as its central signalling molecule.

When fatty acid oxidation dominates, β-oxidation elevates the mitochondrial acetyl-CoA/CoA ratio and simultaneously raises NADH/NAD⁺. Both changes inhibit PDH: elevated acetyl-CoA promotes PDH kinase activity (particularly PDK2 and PDK4), phosphorylating and inactivating PDH, so that glucose-derived pyruvate accumulates instead of entering the TCA cycle. The downstream citrate that accumulates from the now-abundant mitochondrial acetyl-CoA leaks into the cytosol and inhibits phosphofructokinase-1 (PFK-1), suppressing glycolytic flux at a second point. ^[2]

In the reverse direction, when glucose is abundant and insulin elevated, glucose-derived pyruvate generates mitochondrial acetyl-CoA, which exits as citrate and is converted by ACLY to cytosolic acetyl-CoA. ACC then carboxylates it to malonyl-CoA, which potently inhibits CPT-1 – the gatekeeper controlling long-chain fatty acid entry into the mitochondria. With CPT-1 inhibited, fatty acids are rerouted toward esterification rather than oxidation. Acetyl-CoA is therefore both the product of fuel metabolism and the messenger that instructs the cell which fuel source to suppress. ^[2]

Acetyl-CoA and Skin Barrier Biology

In the skin, cytosolic acetyl-CoA has a specific, non-substitutable function: it is the raw material for the fatty acid elongation reactions that produce the very long-chain fatty acids required in the stratum corneum’s ceramide pool. The ELOVL elongase enzymes – particularly ELOVL1, ELOVL3, and ELOVL4 – extend fatty acid chains two carbons at a time through a condensation reaction requiring malonyl-CoA as the two-carbon donor. Malonyl-CoA is produced from cytosolic acetyl-CoA via acetyl-CoA carboxylase (ACC); each elongation step consumes one malonyl-CoA molecule. To extend a C18 fatty acid to C26 requires four elongation cycles; ELOVL4 then continues from C26 toward the ultra-long-chain range (C28–C36+) required for acylceramide subspecies. ^[1]

These ultra-long-chain ceramides – particularly the acylceramides EOS and EOP that generate the long periodicity phase – are structural hallmarks of the competent mammalian skin barrier. Both the elongation and the subsequent ceramide synthesis are carried out at the cytosolic face of the endoplasmic reticulum in differentiating keratinocytes, drawing on the cytosolic malonyl-CoA pool derived from acetyl-CoA. ^[4]

A 2025 study from Nguyen et al. (Cell Reports, University of Pennsylvania) provided direct experimental evidence of the consequences of disrupted skin acetyl-CoA synthesis. Using inducible knockout mouse models, the researchers deleted ACLY alone and in combination with its backup enzyme ACSS2 (which generates cytosolic acetyl-CoA from acetate). Loss of ACLY alone in the skin produced dry, scaly skin, epidermal thickening, enlarged sebaceous glands, and hair changes. When both ACLY and ACSS2 were deleted from the skin, the effects were severe: transepidermal water loss was significantly elevated; lipidomics revealed depletion of ceramides with very long acyl chains (particularly ceramides exceeding 50 total carbons), whilst ceramides with shorter acyl chains (40 carbons or fewer) accumulated. This ceramide chain-length shift represents a qualitative failure of barrier architecture rather than simply a shortage of ceramide material. ^[3]

Critically, dietary olive oil supplementation improved systemic fat depletion and certain skin phenotypes – but did not restore the very long-chain ceramide profile in the epidermis. This confirms that the elongation deficit arose from impaired local acetyl-CoA synthesis, not insufficient circulating fatty acid supply. The ceramides that define a high-integrity barrier cannot be absorbed from the diet or from topical sources; they require intracellular elongation, and that elongation is dependent on cytosolic acetyl-CoA. ^[3]

A secondary finding separates the skin’s two lipid-producing compartments. Sebum production was maintained – and modestly increased – in ACLY/ACSS2-deficient skin, sustained by upregulated CD36 fatty acid transporter activity importing circulating fatty acids from adipose lipolysis. This led to rapid systemic fat depletion as the skin’s demand escalated. Sebaceous glands can compensate for impaired local synthesis by drawing on circulating lipid supply; the epidermis cannot, because the elongation step the barrier depends on requires local cytosolic acetyl-CoA. ^[3]

Clinical Pearl The Nguyen et al. olive oil finding is the key translational insight for barrier conversations: exogenous fatty acids can sustain sebum but cannot rescue very long-chain epidermal ceramides. The barrier’s most structurally critical ceramides are assembled locally, and their assembly requires a substrate – cytosolic acetyl-CoA – that topical products cannot supply. Topical ceramide support remains appropriate and valuable; this finding adds the reason why it may be insufficient as a standalone intervention in clients whose metabolic state is impairing the elongation step.

Fed State, Fasted State, and Barrier Lipid Synthesis

The flow of acetyl-CoA through the citrate shuttle – and therefore cytosolic acetyl-CoA availability for barrier lipid elongation – changes substantially between nutritional states.

In the fed state, glucose-driven insulin elevation promotes GLUT4 translocation, pyruvate flux through PDH is high, and citrate is produced in excess of TCA cycle demand. ACLY exports this citrate-derived acetyl-CoA to the cytosol, fuelling malonyl-CoA production, fatty acid synthesis, elongation, and histone acetylation. This is the metabolic state most conducive to de novo lipid production, including the elongated ceramides the skin barrier depends on.

In the fasted state, insulin falls, lipolysis mobilises fatty acids as the dominant fuel, and mitochondrial acetyl-CoA is directed through the TCA cycle for ATP production; cytosolic acetyl-CoA availability declines correspondingly. De novo lipid synthesis slows. In the liver, excess mitochondrial acetyl-CoA from intensified fat oxidation is packaged as ketone bodies.

The practical implication is that the skin’s capacity for very long-chain ceramide synthesis is not static – it tracks with the fed/fasted cycling that healthy metabolic function provides. Conditions that impair this cycling – metabolic inflexibility, chronic insulin resistance impairing GLUT4-mediated glucose entry, or poorly structured dietary patterns that do not support the citrate export pathway – may contribute to a sustained shortfall in the elongation capacity that barrier ceramide quality depends on. This is mechanistic reasoning from established biology; direct clinical evidence in humans is not yet available, and it should be framed accordingly.